NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
FIGO stage III ovarian cancer who are eligible for primary cytoreductive surgery resulting in non-residual disease, or residual disease up to 2.5 mm
1 total trials
Filter these 1 trials by phase, country, sponsor and more.